Zeev Bovan

$TARA Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics
October 15, 2026 08:00 ET

Little shaking and they be running lol

Smart investors are loading up, there will come a time when $ORCL will be worth north of a 1000$ and those who accumulate today will laugh at the past and enjoy thier future.

$TARA those who are afraid to lose don’t deserve win. Once they get FDA approval they will reach analyst target price and it will just be the beginning of something bigger.

October 09, 2026 - 5 hours ago
Tanker Rates Hit $1.3M a Day As 9 Shipping Stocks Double in 2026

$DHT

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Arcutis Biotherapeutics, Inc.
October 06, 2026 08:19 ET
Newly created award category highlights innovation in prescription skin treatment
ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis

I am on board till the end whether it goes to 0 or I will become a hero. As per the test results things are fine, Bank of America loaded up on $TARA, something is happening, could be happening, shorts closing thier positions or a dump before a huge pump/news.

$TARA hundreds of percent profit as per several analysts

1. THRIVE-3 Trial Interim Results (Estimated Window: November – December 2026)
   • The Milestone: This is the most crucial near-term "success or failure" binary event. The registrational Phase 3 trial is testing IV Choline Chloride for patients dependent on long-term intravenous nutrition.
   • What Success Looks Like: Positive interim data from this study will mathematically validate the drug's efficacy and safety profiles, directly smoothing the path toward regulatory approval.
2. STARBORN-1 Pivotal Trial Update (Estimated Window: November – December 2026)
   • The Milestone: Full enrollment completion and a comprehensive data update from the STARBORN-1 trial evaluating their lead asset, TARA-002, in pediatric lymphatic malformations.
   • What Success Looks Like: Strong efficacy and durability metrics here are critical because the company is actively preparing this exact dataset to support their Biologics License Application (BLA) submission to the FDA

Idiots, put stop loss on future profits, wait till December, that’s when things should start moving.

$CRH bullish from next year, till then more or less flat, that’s my prediction.